OneSource Specialty Pharma Limited (ONESOURCE) Fair Value & Analysis
Healthcare · IN · Market cap ₹191B
Fair value as of: Jul 3, 2026
From 6 valuation models · updated today
Share price −7.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,114 – ₹2,021 · fair‑value band ₹136.05 – ₹308.54 · the ₹1,669 price screens above the ₹222.29 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
OneSource Specialty Pharma Limited (ONESOURCE) currently trades at ₹1,669, while our model-based Fair Value estimate is ₹222.29 — implying the stock looks roughly 86.7% overvalued today. We read business quality at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, OneSource Specialty Pharma Limited generated revenue of ₹14.2B at a net margin of -5.2%. Revenue grew 0.5% year over year. It earns a return on equity of -1.3%. Net debt stands at ₹14.1B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in …
Revenue & earnings trend
FY2023 – FY2026 · reported fiscal years
OneSource Specialty Pharma Limited reported revenue of ₹14.2B in FY2026 versus ₹387M in FY2023, a compound +232.4%/yr. Reported net income was −₹738M in FY2026.
Is ONESOURCE fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is OneSource Specialty Pharma Limited (ONESOURCE) undervalued?
What is the fair value of ONESOURCE?
What is the quality score of ONESOURCE?
What is the revenue of OneSource Specialty Pharma Limited (ONESOURCE)?
What is the net profit margin of ONESOURCE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.